Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

Annals of Clinical and Translational Neurology

Volumn 1, Issue 7, 2014, Pages 490-496

  Lehmann Horn, Klaus ^a,d   Kinzel, Silke ^b   Feldmann, Linda ^b   Radelfahr, Florentine ^a   Hemmer, Bernhard ^a   Traffehn, Sarah ^b   Bernard, Claude C A ^c   Stadelmann, Christine ^b   Brück, Wolfgang ^b   Weber, Martin S ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL DIVISION; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMORAL IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 84950279079     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.71     Document Type: Article

References (14)

1. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676–688.
2. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779–1787.
3. Weber MS, Hemmer B. Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis. Results Probl Cell Differ 2010;51:115–126.
4. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011;1812:239–245.
5. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209:1001–1010.
6. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164–174.
7. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089–1104.
8. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466–468.
9. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010;68:369–383.
10. Rupprecht TA, Angele B, Klein M, et al. Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. J Immunol 2007;178:1861–1869.
11. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935–943.
12. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999;24:511–514.
13. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350–1356.
14. Kida S, Pantazis A, Weller RO. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol 1993;19:480–488.